You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)

    SBC: BIOSTRATAGIES LC            Topic: 105

    PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Development of Gemini-DHAP

    SBC: SFC FLUIDICS, INC.            Topic: 200

    Advanced Development of GeminiTM-DHAP Project Summary:The Specific Aim of this Direct to Phase II project is to develop a discrete, low-profile, dual hormone artificial pancreas device, the GeminiTM-DHAP, using SFC Fluidics' enabling microfluidic technologies to deliver both insulin and glucagon as recommended by a dual-hormone algorithm in response to continuous glucose monitor readings. The Gemi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases

    SBC: Nephropathology Associates, PLC            Topic: 400

    Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy

    SBC: Nephropathology Associates, PLC            Topic: 400

    Project SummaryThe goal of this program is to initiate commercialization of a mass spectrometry (MS)-based workflow for the diagnosis and classification of membranous nephropathy (MN), a leading cause of nephrotic syndrome, leading to kidney failure in a third of patients. Since the 1950’s, most forms of MN were considered idiopathic in origin, however, based on numerous publications in recent y ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. 100 Additional fresh samples for verification of assay to replace the original proposed banked samples that cannot be used due to repeated exposure to freezing and thawing.

    SBC: ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC            Topic: 300

    James, Laura P Project Summary/Abstract The original plan for development of AcetaSTAT was to use banked samples of serum collected from acetaminophen overdose patients to verify the effectiveness of the assay prior to verification and validation efforts. However, during the development of the work it has become apparent that banked samples cannot be used due to their instability and repeated expo ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Commercialization Readiness for Bone Filler Scaffold Device to Aid in Dental Applications and Reconstruction

    SBC: NuShores Biosciences LLC            Topic: NIDCR

    Project Summary Current bone grafting techniques for functional rehabilitation with dental implants have limitations – high-cost, difficulties with fixation and stabilization, insufficient bone regeneration, high morbidity using autogenous block grafts and prolonged healing of up to 9 months. Existing synthetic bone fillers cannot match defect shape and volume, are weakly resorbed if at all, are ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization

    SBC: BIOSTRATAGIES LC            Topic: NICHD

    The long-range goal of this research is to develop an enzyme replacement therapy (ERT) technology for genetic metabolic diseases that is effective in mitigating the problem of immune sensitization that has hindered previous ERT technologies. ERT drugs have been approved for treating almost a dozen lysosomal diseases (LDs), however, the induction of patient anti-ERT antibodies has emerged as a sign ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. CHANGE PI INCLUDE DIAGNOSTIC TO INCLUDE SAR COV-2 SBIR PHASE II REMOTE DIAGNOSTIC READER

    SBC: NOWDiagnostics, Inc.            Topic: 37

    The research proposed here will support seroprevalence studies of SARS CoV-2 antibodies by the use of a rapid test system that can perform multiplexed analyses from remote point-of-care sites and transmit results to a centralized database. A drop of blood is collected from the subject’s fingertip, inserted into the cassette, and the assay is initiated by pressing a button. The assay cassette is ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Noninvasive Home Assessment of Cardiac Filling Pressure to Identify Heart Failure Patients at High Risk for Readmission

    SBC: Vixiar Medical, Inc            Topic: NHLBI

    Congestive heart failure (CHF) is the most common reason for hospitalization in the U.S., with over 1 million admissions per year. Patients admitted with CHF usually need IV diuretics to promote fluid removal. The readmission rate is high – over 20% by 30 days, and 30% by 90 days post-discharge. This also presents an enormous economic burden - hospitalizations account for a large percentage of t ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility study of a nanostructural system for bone regeneration in preparation for dental implants

    SBC: NuShores Biosciences LLC            Topic: NIDCR

    Project Summary Original Fast-Track Project SummaryCurrent bone grafting techniques for functional rehabilitation with dental implants have limitations – high-cost, difficulties with fixation and stabilization, insufficient bone regeneration, high morbidity using autogenous block grafts and prolonged healing of up to 9 months. Existing synthetic bone fillers cannot match defect shape and volume, ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government